Psyched Wellness takes 'key step' by beginning its 14-day oral toxicity study of AME-1

Psyched Wellness Ltd (CSE:PSYC) (OTCQB:PSYCF) (FRA:5U9) CEO Jeff Stevens tells Proactive the group has kicked off the next preclinical trial of AME-1 (extract of the Amanita Muscaria mushroom) along with its clinical research organization, KGK Science.

Stevens says the new study is a 14-day oral toxicity study of AME-1 designed to determine the dosage levels that will be selected and administered for a subsequent 90-day oral toxicity study. The importance of this study is to determine dose-dependent effects and the highest dose that is safe to use for a longer-term study.